- Home
- SCYX vs RDI Comparison
SCYX vs RDI Comparison
Compare SCYX & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCYX
- RDI
- Stock Information
- Founded
- SCYX 1999
- RDI 1937
- Country
- SCYX United States
- RDI United States
- Employees
- SCYX N/A
- RDI N/A
- Industry
- SCYX Biotechnology: Pharmaceutical Preparations
- RDI Movies/Entertainment
- Sector
- SCYX Health Care
- RDI Consumer Discretionary
- Exchange
- SCYX Nasdaq
- RDI Nasdaq
- Market Cap
- SCYX 26.6M
- RDI 27.9M
- IPO Year
- SCYX 2014
- RDI N/A
- Fundamental
- Price
- SCYX $0.88
- RDI $1.27
- Analyst Decision
- SCYX
- RDI
- Analyst Count
- SCYX 0
- RDI 0
- Target Price
- SCYX N/A
- RDI N/A
- AVG Volume (30 Days)
- SCYX 212.7K
- RDI 24.7K
- Earning Date
- SCYX 08-19-2025
- RDI 08-18-2025
- Dividend Yield
- SCYX N/A
- RDI N/A
- EPS Growth
- SCYX N/A
- RDI N/A
- EPS
- SCYX N/A
- RDI N/A
- Revenue
- SCYX $2,630,000.00
- RDI $205,644,000.00
- Revenue This Year
- SCYX $410.22
- RDI $7.47
- Revenue Next Year
- SCYX $248.83
- RDI $13.22
- P/E Ratio
- SCYX N/A
- RDI N/A
- Revenue Growth
- SCYX N/A
- RDI N/A
- 52 Week Low
- SCYX $0.66
- RDI $1.17
- 52 Week High
- SCYX $1.82
- RDI $1.89
- Technical
- Relative Strength Index (RSI)
- SCYX 68.89
- RDI 42.61
- Support Level
- SCYX $0.68
- RDI $1.29
- Resistance Level
- SCYX $0.92
- RDI $1.36
- Average True Range (ATR)
- SCYX 0.04
- RDI 0.06
- MACD
- SCYX 0.02
- RDI -0.00
- Stochastic Oscillator
- SCYX 83.33
- RDI 18.18
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.